FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes Buys 21,000 Shares of Stock

Key Points

• CEO Ryan Rhodes bought 21,000 shares of FocalTherics at an average price of $4.75, investing $99,750 and increasing his ownership by 3.47% to 626,649 shares.
• FocalTherics reported a quarterly loss of $0.39 per share, missing the $0.20 consensus estimate, while generating $13.2 million in revenue. The stock opened at $4.76 and has traded between $1.30 and $6.40 over the past year.
• Analyst sentiment remains mixed, with ratings ranging from “sell” to “strong buy”; the overall consensus is “Hold” with a $7.75 price target. Institutional investors own 62.74% of the company.

FocalTherics (NASDAQ:FOCL - Get Free Report) CEO Ryan Rhodes purchased 21,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $4.75 per share, for a total transaction of $99,750.00. Following the purchase, the chief executive officer owned 626,649 shares in the company, valued at $2,976,582.75. This represents a 3.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

FocalTherics Stock Performance

Shares of FOCL stock opened at $4.76 on Monday. The stock has a market cap of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company's 50-day moving average price is $5.39.

FocalTherics (NASDAQ:FOCL - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. As a group, research analysts predict that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FOCL. Rock Springs Capital Management LP grew its position in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company's stock worth $5,126,000 after purchasing an additional 91,500 shares during the period. Lido Advisors LLC bought a new position in shares of FocalTherics during the 1st quarter valued at $40,000. SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics during the 1st quarter valued at $38,000. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the 4th quarter worth $2,623,000. Finally, Kovack Advisors Inc. purchased a new position in shares of FocalTherics in the 4th quarter worth $53,000. Institutional investors own 62.74% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on FOCL shares. Wall Street Zen cut FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday. Mizuho set a $15.00 target price on FocalTherics and gave the stock an "outperform" rating in a report on Friday, July 17th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target on shares of FocalTherics in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source